Home › Funds › Sarissa Capital Management LP › CYTK

Sarissa Capital Management LP position in CYTK

CYTOKINETICS INC COM NEW · Health Care

Sarissa Capital Management LP reported holding 228,623 shares of CYTK (CYTOKINETICS INC COM NEW) in its Q2 2026 13F filing — a position valued at US$19.5M, representing 10.95% of its reported portfolio and ranking #5 among its reported holdings. Sarissa Capital Management LP has disclosed CYTK holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)228.62K sh
Reported value held$19.48M
Portfolio Weight10.95%
First reportedQ1 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Sarissa Capital Management LP's CYTK position evolved

Sarissa Capital Management LP first disclosed a stake in CYTK in Q1 2024 at 300,000 shares (US$21.0M). The position peaked in Q2 2024 at 1,110,000 shares, worth US$60.1M. Across 10 filings, Sarissa Capital Management LP increased the stake 1 time(s), trimmed it 5 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 228,623 shares valued at US$19.5M. Notable position changes include a 270% increase in Q2 2024 (shares fell 3% over the following quarter), a 33% trim in Q4 2025 (shares rose 4% over the following quarter), a 42% trim in Q1 2026 (shares rose 29% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 300.00K $21.03M New
Q2 2024 1.11M $60.14M Add
Q3 2024 1.11M $58.61M Hold
Q4 2024 833.80K $39.22M Reduce
Q1 2025 600.00K $24.11M Reduce
Q2 2025 588.36K $19.44M Reduce
Q3 2025 588.36K $32.34M Hold
Q4 2025 396.36K $25.18M Reduce
Q1 2026 228.62K $15.07M Reduce
Q2 2026 228.62K $19.48M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CYTK and 13F data

CYTK (CYTOKINETICS INC COM NEW) is a Health Care company. 52 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CYTK

All CYTK fund holders →

FAQ

How long has Sarissa Capital Management LP held CYTK?

Sarissa Capital Management LP has disclosed CYTK holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is Sarissa Capital Management LP's current position in CYTK?

As of Q2 2026, Sarissa Capital Management LP holds 228.62K shares of CYTK (CYTOKINETICS INC COM NEW), valued at $19.48M, representing 10.95% of its reported portfolio and ranking #5.

Has Sarissa Capital Management LP been buying or selling CYTK?

In the latest 13F filing (Q2 2026), Sarissa Capital Management LP held unchanged its position in CYTK. The position peaked in Q2 2024 at 1.11M shares.

Which other funds hold CYTK?

Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.